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Comments, Opinions, and Reviews
Good Laboratory Practice
Preventing Introduction of Bias at the Bench
Malcolm R. Macleod; Marc Fisher; Victoria O’Collins; Emily S. Sena; Ulrich Dirnagl;
Philip M.W. Bath; Alistair Buchan; H. Bart van der Worp; Richard Traystman; Kazuo Minematsu;
Geoffrey A. Donnan; David W. Howells
Background and Purpose—As a research community, we have failed to demonstrate that drugs which show substantial
efficacy in animal models of cerebral ischemia can also improve outcome in human stroke.
Summary of Review—Accumulating evidence suggests this may be due, at least in part, to problems in the design, conduct
and reporting of animal experiments which create a systematic bias resulting in the overstatement of neuroprotective
efficacy.
Conclusions—Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal
experiments modeling human stroke. (Stroke. 2009;40:e50-e52.)
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Nearly 10 years after the first Stroke Therapy AcademicIndustry Roundtable participants established guidelines
intended to support the translation of neuroprotective efficacy
from bench to bedside,1 there is still no clinically effective
neuroprotective drug for stroke. One interpretation of this
observation is that measures outlined in STAIR I have failed
to deliver the promised improvements in drug development.
However, a dispassionate analysis of data presented over the
last 10 years suggests that the “STAIR hypothesis”—that
improvements in animal experimental design will lead to
improvements in translational efficiency—has yet to be
adequately tested. Adhering to standards of conducting and
reporting of experiments in order to reduce the confounding
effects of bias and ensure adequate statistical power, as
outlined below, will increase the confidence with which we
can assess new data and maximize our chances of developing
effective therapies.
The original STAIR proposal was that by paying due
attention to experimental bias, to the breadth of physiological
variables known to influence stroke outcome in patients, and
by testing therapies in a range of model systems which might
more faithfully reproduce the key facets of stroke pathophys-
iology, we would be able to translate what appeared to be
clear evidence of neuroprotective efficacy in animals to the
more heterogeneous circumstances of human stroke. Al-
though we believe strongly that failure to adequately consider
variables such as age, comorbidity, physiological status, and
timing of drug administration contribute to the disparity
between the results of animal models and clinical trials, they
have been reviewed elsewhere1,2 and are not the subject of
this article.
Analyses of data supporting the efficacy of various neuro-
protective strategies3–5 have revealed that although many
researchers adhere closely to the ethos of these guidelines, as
a community we do not. A simple checklist derived from the
STAIR guidelines to provide an overview of the range of data
available for 1026 candidate therapies4 revealed that only a
handful came close to meeting the STAIR guidelines. A
higher score against this checklist was accompanied by a
marked reduction in effect size. This later trend could be seen
clearly even within the data for individual drugs.6 Moreover,
studies which reported measures to avoid bias such as random
allocation to treatment group, blinded induction of ischemia
or the blinded assessment of outcome,7,8 gave a markedly
lower estimate of efficacy. Despite this, there has been some
evidence of improvement in study quality, and the perfor-
mance of animal stroke studies is substantially better than that
for most other models of neurological disease.5 And yet, the
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majority of investigators still do not report whether or not
they took measures to avoid bias.
Systematic reviews and meta-analyses of data from animal
stroke studies suggest that these studies may be substantially
distorted by experimental bias. Taken together, publications
supporting the efficacy of NXY-059 include randomized data
with allocation concealment and blinded outcome assess-
ment, but most individual publications do not report these
measures. Analyses of those data suggests that at least half of
the reported 44% improvement in outcome could be attrib-
uted to experimental bias, specifically a failure to randomize
the allocation to experimental group, a failure to conceal
treatment group allocation from the surgeon or a failure to
blind the assessment of outcome.8 Similar observations have
been made of the hypothermia literature, where nonrandom-
ized studies and studies without blinded outcome assessment
appear to give a relative overstatement of efficacy of 27% and
19%, respectively.7 Despite the widely recognized impor-
tance of these aspects of study design, analyses conducted by
the CAMARADES group suggest that only 36% of studies
reported random allocation to treatment group, only 11%
report allocation concealment and only 29% reported the
blinded assessment of outcome.5
A related issue is the number of animals used in experi-
ments. The probability of detecting a difference of a given
size between groups is related to the number of animals in
each group, the size of the difference and the variability in the
outcome measure used. However, only 3% of studies identi-
fied in systematic reviews reported using a sample size
calculation.5 Importantly, if sample size calculations are
based on falsely large estimates of effect size, studies will not
be powered to detect real differences between treatment and
control groups. Indeed, post hoc analysis suggests that most
experimental stroke studies have only a 1 in 3 chance of
detecting a 20% difference in outcome.
These problems are not unique to the preclinical study of
stroke. Clinical stroke trials have had problems with inade-
quate sample size9 and have also failed to report whether they
took measures to avoid bias.10 Indeed Cochrane’s observation
that “when humans have to make observations there is always
the possibility of bias”11 was a lynchpin of the CONSORT
(Consolidated Standards of Reporting Trials) initiative to
improve the reporting, design, conduct, analysis, and inter-
pretation of randomized controlled trials to inform decision-
making in health care.11,12 This initiative led to substantial
improvements in the reporting and conduct of clinical trials.13
On the basis of the available evidence, it would now seem
reasonable to suggest that preclinical testing in animal models
of stroke, and indeed other models of disease, should adopt
similar standards to ensure that decision-making is based on
high quality unbiased data.5,14 Adoption of such standards
would have the added benefit of reducing wasteful use of
financial and animal resources.
In general, studies should only be considered for publica-
tion if their Methods section includes a description of how
they have addressed the standards below, or if authors make
a cogent argument for why these standards are not relevant to
their work. For these components of an article, citation of
methods described in previous publications is not considered
sufficient. These requirements should not preclude publica-
tion of important observational, pilot or hypothesis-
generating data, but the conclusions of such studies should
reflect their preliminary nature.
Animals
The precise species, strain, substrain and source of animals
used should be stated. Where applicable (for instance in
studies with genetically modified animals) the generation
should also be given, as well as the details of the wild-type
control group (for instance littermate, back cross etc).
Sample Size Calculation
The manuscript should describe how the size of the experi-
ment was planned. If a sample size calculation was performed
this should be reported in detail, including the expected
difference between groups, the expected variance, the
planned analysis method, the desired statistical power and the
sample size thus calculated. For parametric data, variance
should be reported as 95% confidence limits or standard
deviations rather than as the standard error of the mean.
Inclusion and Exclusion Criteria
Where the severity of ischemia has to reach a certain
threshold for inclusion (for instance a prespecified drop in
perfusion detected with laser-Doppler flowmetry, or the
development of neurological impairment of a given severity)
this should be stated clearly. Usually, these criteria should be
applied before the allocation to experimental groups. If a
prespecified lesion size is required for inclusion this should
be detailed, as well as the corresponding exclusion criteria.
Randomization
The manuscript should describe the method by which animals
were allocated to experimental groups. If this allocation was
by randomization, the method of randomization (coin toss,
computer-generated randomization schedules) should be
stated. Picking animals ‘at random’ from a cage is unlikely to
provide adequate randomization. For comparisons between
groups of genetically modified animals (transgenic, knock-
out), the method of allocation to for instance sham operation
or focal ischemia should be described.
Allocation Concealment
The method of allocation concealment should be described.
Allocation is concealed if the investigator responsible for the
induction, maintenance and reversal of ischemia and for
decisions regarding the care of (including the early sacrifice
of) experimental animals, has no knowledge of the experi-
mental group to which an animal belongs. Allocation con-
cealment might be achieved by having the experimental
intervention administered by an independent investigator, or
by having an independent investigator prepare drug individ-
ually and label it for each animal according to the random-
ization schedule as outlined above. These considerations also
apply to comparisons between groups of genetically modified
animals, and if phenotypic differences (eg, coat coloring)
prevent allocation concealment this should be stated.
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Reporting of Animals Excluded From Analysis
All randomized animals (both overall and by treatment
group) should be accounted for in the data presented. Some
animals may, for very good reasons, be excluded from
analysis, but the circumstances under which this exclusion
will occur should be determined in advance, and any exclu-
sion should occur without knowledge of the experimental
group to which the animal belongs. The criteria for exclusion
and the number of animals excluded should be reported.
Blinded Assessment of Outcome
The assessment of outcome is blinded if the investigator
responsible for measuring infarct volume, for scoring neu-
robehavioural outcome or for determining any other outcome
measures has no knowledge of the experimental group to
which an animal belongs. The method of blinding the
assessment of outcome should be described. Where pheno-
typic differences prevent the blinded assessment of for
instance neurobehavioural outcome, this should be stated.
Reporting Potential Conflicts of Interest and
Study Funding
Any relationship which could be perceived to introduce a
potential conflict of interest, or the absence of such a
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We consider that these measures are of central importance
to Good Laboratory Practice in the modeling of cerebral
ischemia. Many groups already perform experiments to these
high standards, and we hope that they will now report this in
full, and that others follow their lead. Finally, we do not
consider these requirements to represent a final or complete
list of appropriate measures necessary to avoid bias. Future
additions may be required as further evidence emerges and
the experience of authors and reviewers evolves.
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